Pharmaceutical composition for alleviating or treating premenstrual syndrome comprising enterococcus faecium LCM001 strain

Abstract

The present invention relates to a pharmaceutical composition, a food composition, and a health functional food composition for alleviating or treating premenstrual syndrome, all comprising as an active ingredient one or more selected from the group consisting of Enterococcus faecium LCM001 strain (accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and a dead cell mass of the strain.

Description

Pharmaceutical composition for alleviating or treating premenstrual syndrome comprising Enterococcus faecium LCM001 strain

[0001] The present invention relates to a pharmaceutical composition, a food composition and a health functional food composition for alleviating or treating premenstrual syndrome, which comprises as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture and dead cells of the strain.

[0002] Premenstrual syndrome (PMS) is a condition characterized by recurring mental, emotional, and physical symptoms that begin a few days to weeks before menstruation and disappear once menstruation begins. PMS typically begins in women in their late teens or early twenties, and symptoms are reported to be more prevalent and more severe in women in their twenties than in other age groups. Previous studies have reported that 8% of women between the ages of 21 and 35 experience severe PMS, and 14% experience moderate PMS.

[0003] When PMS is accompanied by severe social maladjustment and disturbances that make daily life impossible, it is classified as a psychiatric illness and named premenstrual dysphoric disorder (PMDD). International Classification of Diseases (ICD, 10) thAccording to the ICD-10 (Revision), PMS can be diagnosed when one or more of the seven symptoms of minor psychological discomfort, bloating, weight gain, breast tenderness, muscular tension or aches, poor concentration, and changes in appetite are present and are limited to the luteal phase.

[0004] In the United States and the United Kingdom, approximately one-third of women of childbearing age report experiencing PMS, and of these, approximately 10% report symptoms severe enough to interfere with their daily lives. In Korea, the prevalence of PMS varies somewhat among researchers, but Lee (1988) reported that 94% of female college students experience PMS, with 53.2% reporting severe PMS. Furthermore, Park (2001) reported a higher prevalence of PMS, ranging from 22.9% to 48.6%. Previous domestic and international studies on premenstrual discomfort have shown that greater PMS is associated with greater negative emotions and attitudes in daily life (Kim Young-hee, 2002). As previous studies have shown, PMS negatively impacts women's academic and work performance by reducing their productivity. It also weakens relationships with family and colleagues, leading to social and economic harm. In severe cases, it can even lead to increased incidents of child abuse, suicide attempts, and missing persons. Many women living in modern society experience psychological symptoms like fatigue and low mood in the period leading up to their period, as well as physical symptoms like headaches, abdominal pain, and backache. They believe these symptoms are signs of impending menstruation, but they struggle to find specific prevention or treatment methods. Therefore, it's crucial to develop strategies to overcome PMS, which negatively impacts academics and careers.

[0005] The present invention provides a pharmaceutical composition, food composition and health functional food composition for alleviating or treating premenstrual syndrome, which comprises as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture and a dead cell of the strain.

[0006] However, the problems that the present invention seeks to solve are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

[0007] In order to achieve the above purpose, the present invention provides a pharmaceutical composition for alleviating or treating premenstrual syndrome, containing as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

[0008] The above strain is characterized by having a 16s RNA base sequence of [SEQ ID NO: 1].

[0009] The above effective ingredient is characterized by reducing the amount of prolactin secretion.

[0010] The above effective ingredient is characterized by reducing the amount of luteinizing hormone (LH) secretion.

[0011] The above effective ingredient is characterized by increasing the amount of follicle stimulating hormone (FSH) secretion.

[0012] The above effective ingredient is characterized by reducing the amount of prostaglandin E2 (PGE2) secretion.

[0013] In another embodiment of the present invention, a food composition for alleviating or improving premenstrual syndrome is provided, which contains as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

[0014] In another embodiment of the present invention, a food additive composition for alleviating or improving premenstrual syndrome is provided, which contains as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

[0015] In another embodiment of the present invention, a health functional food composition for alleviating or improving premenstrual syndrome is provided, which contains as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

[0016] The Enterococcus faecium LCM001 strain culture of the present invention (Accession No.: KCTC 14669BP) exhibits an excellent prolactin secretion inhibitory effect, and restores the amount of LH secretion increased by estradiol to a level similar to that of the normal group, restores the amount of FSH hormone secretion suppressed by estradiol to a level similar to that of the normal group, and restores the amount of PGE2 secretion increased by estradiol to a level similar to that of the normal group. Therefore, the Enterococcus faecium LCM001 strain culture can be applied to food compositions, health functional food compositions, pharmaceutical compositions, etc. for alleviating or treating premenstrual syndrome.

[0017] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the detailed description of the present invention or the composition of the invention described in the claims.

[0018] Figure 1 is a graph measuring the amount of prolactin secreted after treating each sample in the GH3 cell line.

[0019] Figure 2 is a graph measuring the amount of luteinizing hormone (LH) secreted after treating each sample in the GH3 cell line.

[0020] This graph shows the amount of follicle-stimulating hormone (FSH) secreted after each sample was treated in the GH3 cell line.

[0021] Figure 4 is a graph measuring the amount of prostaglandin E2 (PGE2) secreted after treating each sample in the GH3 cell line.

[0022] The present invention provides a pharmaceutical composition for alleviating or treating premenstrual syndrome, containing as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

[0023] Specific structural or functional descriptions of the embodiments of the present invention disclosed in this specification or application are merely illustrative for the purpose of describing embodiments according to the present invention, and embodiments according to the present invention may be implemented in various forms and should not be construed as limited to the embodiments described in this specification or application.

[0024] Since embodiments of the present invention can be modified in various ways and take various forms, specific embodiments are illustrated in the drawings and described in detail in this specification or application. However, this is not intended to limit embodiments of the present invention to specific disclosed forms, but rather to encompass all modifications, equivalents, and alternatives falling within the spirit and technical scope of the present invention.

[0025] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and shall not be construed in an idealized or overly formal sense unless explicitly defined herein.

[0026]

[0027] The present invention provides a pharmaceutical composition for alleviating or treating premenstrual syndrome, containing as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

[0028] The present inventors identified and characterized a microorganism having a premenstrual syndrome alleviation effect, and discovered that a culture of the Enterococcus faecium LCM001 strain has an excellent premenstrual syndrome alleviation or treatment effect.

[0029] Accordingly, the inventors of the present invention analyzed the 16s rRNA base sequence of the novel Enterococcus faecium LCM001 strain and analyzed the genetic phylogenetic tree, and confirmed that it belongs to Enterococcus and shows 85% homology with Enterococcus faecium. The Enterococcus faecium LCM001 strain was deposited at the Korea Center for Biological Resources (KCTC) under the accession number KCTC 14669BP.

[0030] The 16s rRNA base sequence of the Enterococcus faecium LCM001 strain is as follows: [SEQ ID NO: 1];

[0031] [Sequence number 1]

[0032] GAGATAGACCTTCCCCTTCGGGGGCAAAGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTGTTAGTTGCCATCATTCAGTTGGGCACTCTAGCAAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACG TGCTACAATGGGAAGTACAACGAGTTGCGAAGTCGCGAGGCTAAGCTAATCTCTTAAAGCTTCTCTCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGCCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCACGAGAGTTTGTAACACCAGATGTCGGTGAGGTAACC.

[0033] The term "culture" of the present invention means the entire medium including the strain, bacterial extract, metabolites thereof, extra nutrients, etc. obtained by culturing the Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP) for a certain period of time in a medium capable of supplying nutrients so that the strain can grow and survive, but also includes a culture solution from which the strain is removed after culturing the strain.

[0034] The above culture solution may be left to stand for a certain period of time, and only the upper liquid may be taken, excluding the portion that has settled to the lower layer, or the bacterial cells may be removed through filtration, or the culture solution may be centrifuged to remove the lower sediment and only the upper liquid may be taken. This culture solution may also be concentrated using a conventional method and used as a concentrate.

[0035] The above culture solution or concentrate of the culture solution can be dried by a conventional method and provided as a dried product.

[0036] The term "culture" as used herein, unless otherwise specified, includes a culture solution of the aforementioned fungi, a concentrate of the culture solution, or a dried product of the culture solution or concentrate. The culture may or may not contain fungi, and the inclusion or absence of fungi is not particularly problematic.

[0037] It is preferable that the above culture be obtained by inoculating Enterococcus faecium LCM001 strain into a sterilized MRS broth medium and culturing for 12 hours or more.

[0038] The above-mentioned dead cells are characterized by being manufactured by a method including the steps of 1) culturing Enterococcus faecium LCM001 strain; 2) autoclaving the culture solution; and 3) concentrating and drying using a membrane filtration concentrator to make it into powder.

[0039] In the above culture step, it is preferable to inoculate the Enterococcus faecium LCM001 strain into a sterilized MRS broth medium and culture it for 12 hours or more.

[0040] It is preferable to autoclave the above culture medium at 100 to 121°C for 30 to 60 minutes.

[0041] The above membrane filtration concentrator may have a membrane size of 0.1 to 1㎛, but is not limited thereto.

[0042] The above dead cell powder is 4.0 X 10 12 ~ 6.0 X 10 12 The concentration may be, but is not limited to, cells / g.

[0043] The culture solution of the Enterococcus faecium LCM001 strain (accession number: KCTC 14669BP) above shows an excellent effect in alleviating or treating premenstrual syndrome.

[0044] According to the inventor's experiment, the culture medium (preferably culture medium powder) of the Enterococcus faecium LCM001 strain (accession number: KCTC 14669BP) exhibited an excellent prolactin secretion inhibitory effect, and restored the LH secretion amount increased by estradiol to a level similar to that of the normal group, restored the FSH hormone secretion amount suppressed by estradiol to a level similar to that of the normal group, and restored the PGE2 secretion amount increased by estradiol to a level similar to that of the normal group.

[0045] The pharmaceutical composition for alleviating or treating premenstrual syndrome may be prepared as a composition in a conventional dosage form by selecting one or more active ingredients selected from the group consisting of the Enterococcus faecium LCM001 strain of the present invention (Accession No.: KCTC 14669BP) as the main ingredient, a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain, in addition to one or two or more pharmaceutically acceptable conventional carriers or one or two or more additives.

[0046] The carrier may be selected from one or more of diluents, lubricants, binders, disintegrants, sweeteners, stabilizers, and preservatives, and the additive may be selected from one or more of flavorings, vitamins, and antioxidants.

[0047] In the present invention, any pharmaceutically acceptable carrier and additive may be used. Specifically, as a diluent, lactose monohydrate, trehalose, cornstarch, soybean oil, microcrystalline cellulose, or D-mannitol is preferable, as a lubricant, magnesium stearate or talc is preferable, and as a binder, polyvinyl pyrrolidone (PVP) or hydroxypropylcellulose (HPC) is preferable. In addition, it is preferable to select from among carboxymethylcellulose calcium (Ca-CMC), sodium starchglycolate, polacrylin potassium, or cross-linked polyvinylpyrrolidone as a disintegrant, white sugar, fructose, sorbitol, or aspartame as a sweetener, carboxymethylcellulosesodium (Na-CMC), β-cyclodextrin, white bee's wax, or xanthan gum as a stabilizer, and methyl p-hydroxy benzoate (methylparaben), propyl p-hydroxybenzoate (propylparaben), or It is preferable to choose from potassium sorbate, but it is not limited thereto.

[0048] The pharmaceutical composition of the present invention can be administered to a patient as a single dose, or can be administered by a fractionated treatment protocol in which multiple doses are administered over a long period of time. The term "pharmaceutically effective amount" as used herein refers to an amount that produces a greater response than a negative control group, and preferably refers to an amount sufficient to prevent or treat an inflammatory disease. In addition, the pharmaceutically effective amount may be appropriately varied depending on various factors, such as the disease and its severity, the patient's age, weight, health status, sex, route of administration, and treatment period.

[0049] The composition of the present invention can be formulated in various ways according to the route of administration using a method known in the art together with the pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable" refers to a non-toxic composition that is physiologically acceptable, does not inhibit the action of the active ingredient when administered to humans, and does not typically cause allergic reactions such as gastrointestinal disorders or dizziness or similar reactions. The composition of the present invention can be formulated in various ways according to the route of administration using a method known in the art together with the pharmaceutically acceptable carrier. The route of administration is not limited thereto, but may be administered orally or parenterally.

[0050] According to another embodiment of the present invention, a food composition for preventing lung cancer is provided, which comprises as an active ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and killed cells of the strain.

[0051] According to another embodiment of the present invention, a food additive composition for preventing lung cancer is provided, which comprises as an active ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and killed cells of the strain.

[0052] According to another embodiment of the present invention, a health functional food composition for preventing lung cancer is provided, which comprises as an active ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

[0053] The food, food additive or health functional food of the present invention may be a beverage (including tea or alcoholic beverages), fruit and processed foods thereof (e.g., canned fruit, bottled fruit, jam, marmalade, etc.), fish, meat and processed foods thereof (e.g., ham, sausage, corned beef, etc.), bread and noodles (e.g., udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g., butter, cheese, etc.), edible vegetable oil, margarine, vegetable protein, retort food, frozen food, various seasonings (e.g., soybean paste, soy sauce, sauce, etc.), etc., including the food composition.

[0054] The food, food additive or health functional food of the present invention may additionally include flavoring agents, colorants, thickeners, pH regulators, stabilizers, preservatives, etc. independently or in combination, but is not limited thereto.

[0055] In addition, the food, food additive, or health functional food of the present invention may be formulated as a tablet, pill, powder, granule, powder, capsule, liquid, etc. They may be formulated by further including one or more of a carrier, diluent, excipient, and additive.

[0056] The above food, food additive or health functional food is preferably in liquid, granular or powder form, and in the case of the above food, food additive or health functional food, particularly the food additive composition, it may be manufactured in liquid, granular or powder form and mixed into general food during cooking or consumption.

[0057] Specific examples of the carrier, excipient, diluent and additive include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methylcellulose, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil, and it is preferable to use at least one selected from the group consisting of:

[0058]

[0059] Hereinafter, the composition and effects of the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and the scope of the present invention is not limited by these examples.

[0060]

[0061] Example 1. Isolation and identification of Enterococcus faecium LCM001 strain

[0062] <Microorganism isolation>

[0063] The inventor of the present invention, in order to select a strain having an effect of alleviating or treating premenstrual syndrome, confirmed the effect of alleviating or treating premenstrual syndrome using microorganisms isolated from human feces, and isolated a total of four strains, and selected the microorganism having the best effect of alleviating or treating premenstrual syndrome.

[0064]

[0065] Microbial Identification

[0066] As a result of analyzing the 16s rRNA base sequence of the selected strain, it was confirmed that it had the base sequence of [Sequence Number 1], and as a result of analyzing the genetic phylogenetic tree, it belonged to Enterococcus and showed 85% homology with Enterococcus faecium.

[0067] The inventor named the strain as Enterococcus faecium LCM001 and deposited it with the Korea Center for Biological Resources (KCTC) on August 23, 2021, under the deposit number KCTC 14669BP.

[0068]

[0069] <Preparation of the sample>

[0070] Strains were cultured 1*10 in LB, GAM or TSB medium. 5 After inoculation with CFU / g, the culture was cultured at 37°C for 48 hours. After 24 hours, the strain culture was concentrated to 50 brix using a vacuum concentrator, and then freeze-dried to produce a powder. The produced freeze-dried powder was treated at a concentration of 100 ug / ml.

[0071]

[0072] Example 2. Confirmation of the effect of alleviating or treating premenstrual syndrome.

[0073] The above microorganism Enterococcus faecium LCM001 was inoculated with a single colony in TSB (Tryptic soy broth) autoclaved at 121°C for 15 minutes, and then cultured at 150 rpm in an incubator at 37°C for 24 hours.

[0074] The GH3 cell line was purchased from ATCC, and the cells were cultured in Ham's F12K medium supplemented with 15% horse serum, 2.5% FBS, and 1% P / S.

[0075] After seeding 1*10^5 cells / well in a 24-well plate, the cells were cultured for 24 hours. After replacing the medium with Ham's F12 medium containing 10% charcoal FBS, the cells were cultured for 24 hours, and 10 -9 Hormone secretion in cell lines was regulated by treatment with estradiol from M.

[0076] Afterwards, the samples were treated at a concentration of 100 μg / ml and cultured for 24 hours. The supernatant was then used to measure the concentrations of prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prostaglandin E2 (PGE2). Hormone secretion concentrations were confirmed at 405 nm using an ELISA kit.

[0077] The samples used were the four strains (A, B, C, and Enterococcus faecium LCM001) isolated above and the Lactobacillus paracasei JS1 (Accession No.: KCCM12288P) strain effective for premenstrual syndrome, which the inventor applied for on September 16, 2021.

[0078]

[0079] 1. Changes in prolactin secretion

[0080] Referring to Figure 1, it was confirmed that the amount of prolactin secretion increased by estradiol was reduced by Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP).

[0081] The above strain showed a much better prolactin secretion reduction effect than the previously applied Lactobacillus paracasei JS1 strain.

[0082] Prolactin regulates the female menstrual cycle, and currently, the only treatment for premenstrual syndrome studied involves suppressing prolactin secretion. Therefore, the Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP) of the present invention has been confirmed to have potential as a composition for improving premenstrual syndrome.

[0083]

[0084] 2. Changes in luteinizing hormone (LH) secretion

[0085] Referring to Figure 2, the amount of luteinizing hormone (LH) secretion increased by estradiol was restored to a level similar to that of the normal group by Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP).

[0086] The above strain showed a superior effect of reducing luteinizing hormone (LH) secretion compared to the previously applied Lactobacillus paracasei JS1 strain.

[0087] Luteinizing hormone (LH) is a gonadotropin secreted from the anterior pituitary gland that binds to receptors in the ovaries to increase the production of sex hormones and promote the formation of gametes. The concentration of luteinizing hormone (LH) in the blood increases during menopause.

[0088] Additionally, a rapid increase in luteinizing hormone (LH) induces ovulation, the release of eggs from the ovaries, leading to premenstrual syndrome symptoms such as breast tenderness, bloating, lethargy, depression, and irritability. Therefore, it has been confirmed that the aforementioned microorganisms can improve PMS symptoms.

[0089]

[0090] 3. Changes in follicle-stimulating hormone (FSH) secretion

[0091] Referring to Figure 3, the amount of follicle-stimulating hormone (FSH) secretion suppressed by estradiol was restored to a level similar to that of the normal group by Enterococcus faecium LCM001 strain (Accession Number: KCTC 14669BP).

[0092] The above strain showed a recovery effect more similar to the normal group than the previously applied Lactobacillus paracasei JS1 strain.

[0093]

[0094] *FSH hormone is a gonadotropin that binds to receptors in the ovaries to increase the production of sex hormones and promote the formation of gametes, thereby promoting the development of follicles and ovulation.

[0095]

[0096] 4. Measurement of prostaglandin E2 (PGE2) secretion

[0097] Referring to Fig. 4, the secretion amount of prostaglandin E2 (PGE2) increased by estradiol was suppressed by the Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP), and among the samples, the Enterococcus faecium LCM001 strain (Accession No.: KCTC 14669BP) was regulated to a value most similar to that of the normal group.

[0098] The above strain showed a recovery effect more similar to the normal group than the previously applied Lactobacillus paracasei JS1 strain.

[0099] Prostaglandins are substances that regulate various physiological functions, including the central nervous system, water-electrolyte balance, digestive function, and uterine contractions. Problems with the regulation of these prostaglandins can lead to symptoms of premenstrual syndrome (PMS), including mood disturbances, headaches, breast tenderness, abdominal bloating and pain, edema, and weight gain.

[0100]

[0101] While the present invention has been described herein with a focus on limited embodiments, various other embodiments are possible within the spirit and scope of the invention. Furthermore, although not described, equivalent means may also be incorporated into the present invention. Therefore, the true scope of protection of the present invention should be defined by the following claims.

[0102]

[0103] [Accession number]

[0104] Name of depositor: Korea Research Institute of Bioscience and Biotechnology, Biological Resource Center (KCTC)

[0105] Accession number: KCTC14669BP

[0106] Date of acceptance: 20210823

[0107]

[0108] [Deposit Certificate]

[0109] [Correction pursuant to Rule 91, January 12, 2024]

Claims

1. A pharmaceutical composition for alleviating or treating premenstrual syndrome, containing as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession Number: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

2. In paragraph 1, A pharmaceutical composition for alleviating or treating premenstrual syndrome, characterized in that the strain has a 16s RNA base sequence of [sequence number 1].

3. In paragraph 1, A pharmaceutical composition for alleviating or treating premenstrual syndrome, characterized in that the above effective ingredient reduces the amount of prolactin secretion.

4. In paragraph 1, The above effective ingredient is a pharmaceutical composition for alleviating or treating premenstrual syndrome, characterized by reducing the amount of luteinizing hormone (LH) secretion.

5. In paragraph 1, A pharmaceutical composition for alleviating or treating premenstrual syndrome, characterized in that the above effective ingredient increases the amount of follicle stimulating hormone (FSH) secretion.

6. In paragraph 1, A pharmaceutical composition for alleviating or treating premenstrual syndrome, characterized in that the above effective ingredient reduces the amount of prostaglandin E2 (PGE2) secretion.

7. A food composition for alleviating or improving premenstrual syndrome, containing as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession Number: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

8. A health functional food composition for alleviating or improving premenstrual syndrome, containing as an effective ingredient at least one selected from the group consisting of Enterococcus faecium LCM001 strain (Accession Number: KCTC 14669BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, an extract of the culture, and dead cells of the strain.

Images